Stock comparison
Genmab A/S
Theravance Biopharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
TBPH
Theravance Biopharma
Market cap
$843.92M
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | TBPH | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 53D | GMAB |
| Benjamin Graham | 64C | 51D | GMAB |
| Philip Fisher | 48D | 45D | GMAB |
| Peter Lynch | 25F | 53C | TBPH |
| Joel Greenblatt | 76B | 36D | GMAB |
| Charlie Munger | 68C | 39D | GMAB |
| Terry Smith | 71C | 56C | GMAB |
Side-by-side metrics
| Metric | GMAB | TBPH |
|---|---|---|
| Market cap | $16.5B | $843.92M |
| P/E (TTM) | 6.2x | 7.4x |
| EV/EBIT | 12.0x | - |
| ROIC (TTM) | 43.78% | -1.32% |
| Gross margin | 93.88% | 104.1% |
| Net margin | 18.23% | 104.34% |
| Revenue CAGR 5y | -18.45% | 18.06% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs -1.32%+103%
- Market cap$16.5Bvs $843.92M+95%
- Debt / Equity0.1xvs 0.3x+71%
- P/E (TTM)6.2xvs 7.4x+16%
TBPH leads on
- Revenue CAGR 5y18.06%vs -18.45%+198%
- EV/EBIT-vs 12.0x+125%
- Net margin104.34%vs 18.23%+83%
- Gross margin104.1%vs 93.88%+10%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.